The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The new chip enables the firm's digital PCR system to test up to 240 samples per day, and also uses lower volumes of sample input.
The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.
At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.
The European firm will use the funds to commercialize its Naica digital PCR system and develop clinical applications.
Roche said at the AMP annual meeting that it plans to commercialize the system in Europe with CE IVD marking for clinical applications and in the US with a 510(k) exemption.
The China-based company said that it now has 11 products that have been CE marked, and has applied for additional CE certification for other tests.
The firm has provided glimpses into its strategies for developing a line of regulated droplet digital PCR tests in a number of recent forums.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.